Varenicline significantly increased biochemically verified continuous vaping abstinence rates in youth who vape nicotine daily but do not regularly smoke tobacco.
During weeks 9-12, 51% of youth on varenicline achieved continuous abstinence compared to 14% on placebo, and 6% in enhanced usual care.
Varenicline was well tolerated with no drug-related serious adverse events; adverse events were comparable across groups.
Behavioral counseling combined with pharmacotherapy is an effective strategy to address nicotine vaping, an emerging public health concern in adolescents and young adults.
very interesting subject , great post.